Multiple Myeloma Forums

Onyx drug shows promise in multiple myeloma study

Last Updated on Tuesday, 22 December 2009 22:13 Wednesday, 09 December 2009 01:46

Myeloma Forums - Myeloma Forums

User Rating: / 0
PoorBest 

NEW YORK, Dec 7 (Reuters) - An experimental cancer drug recently acquired by Onyx Pharmaceuticals Inc showed promising response rates in patients with relapsed and/or refractory multiple myeloma, according to interim data from a pair of small mid-stage trials.

The studies, presented on Monday at the American Society of Hematology (ASH) meeting in New Orleans, tested carfilzomib given intravenously every 28 days in 73 patients who had not previously been treated with Takeda Pharmaceuticals' Velcade, and in 33 others following treatment with Velcade.

"These interim results suggest that carfilzomib could benefit patients with multiple myeloma who are no longer responding to current therapies," Dr. David Siegel, co-investigator of the studies, said in a statement.

Onyx acquired carfilzomib with its purchase last month of Proteolix Inc, saying the drug for multiple myeloma, a blood cancer, has the potential for accelerated U.S. approval in 2011.

Read more at publishers website